The global immunoassay analyzers market size was around USD 10.14 billion in 2021 and is estimated to reach USD 28.18 billion by 2030, expanding at a CAGR of 15.7% during the forecast period, 2022–2030. The market growth is attributed to the increasing demand for immunoassay in order to detect and diagnose bacteria and virus-based infections and diseases.
Immunoassay analyzers are medical devices that are used for the immunoassay test which aids in the detection of a specific protein in a particular blood sample. This equipment determines the presence or quantity of proteins in analyte samples using the principles of antigen-antibody binding. Immunoassays play a vital role in treatment planning and disease diagnosis. Hospitals and clinical laboratories employ a clinical immunoassay analyzer for allergy testing, drug monitoring, and the diagnosis of infectious diseases.
Samples that are collected from individuals undergo various immunoassay analyzer tests including enzyme, fluorescence polarization, ion capture, and chemiluminescence. Antibodies are used in immunoassay testing to find minute biological components in blood and other body fluids. The process is based on the idea that specific antigens attach to specific antibodies, inducing an immunological response.
Immunoassay automation offers many advantages to labs, including the potential to easily extend their product line, boost productivity and profitability, and enhance analytical performance. However, manually carrying out immunoassay requires a lot of work and relies on techniques that can differ from user to user.
COVID-19 Impact
The research report finds that the COVID-19 pandemic opened up various growth opportunities for the global immunoassay analyzers market. Immunoassay analyzers are regarded as cornerstones in the management of pandemics due to the increasing demand for diagnostic solutions. Confirmatory testing enables quick virus diagnosis and stops future transmission by isolating individuals.
In order to combat the COVID-19 pandemic, mass testing has gained attention. European countries such as Russia, France, U.K., Italy, Spain, and Germany have reported a maximum number of COVID-19 cases as government organizations conducted mass COVID-19 testing. Therefore, government organizations undertaking a series of initiatives to increase the number of analyzers, instruments, and testing kits in order to boost the testing rate in their countries.
Immunoassay Analyzers Market Dynamics
The market research report presents a complete overview by providing a detailed analysis of the current market trends, existing drivers, growth opportunities, and emerging challenges. The global immunoassay analyzers market report offers up-to-date information about factors that can shape the market outcome or overall performance during the forecast period, 2022 to 2030.
Major Drivers
Increasing incidence of chronic and infectious diseases
The increasing incidence of chronic and infectious diseases is anticipated to drive market growth in the coming years. The growing requirement to control and reduce the incidence of serious diseases and increasing demand for immunoassays to diagnose and detect infections caused by various microorganisms are key factors that contribute to the growth of the immunoassay analyzers market.
Current Restraints
Low detection limit of existing technology
The low detection limit of existing technology is expected to hamper the market during the forecast period. Immunoassay is not adapted to a multianalyte method as each antibody binds to a single analyte or class of analyte. Antibodies show cross-reactivity, they bind to structural analogs of the analyte of interest.
Other issues involve the unsuitability for high-throughput screening analysis, the need for high sample volumes for detection, complex workflows, and reagent instability. Moreover, immunoassay is associated with false negatives during the early stage of the infections. The slightly symptomatic to asymptomatic individuals with low titer of antibodies in response to the coronavirus infections struggle with this incorrect sensitivity.
Market Opportunities
Rising demand for automated and portable immunoassay systems
The rising demand for automated and portable immunoassay systems is projected to create lucrative opportunities for the key market players. Automation provides high efficacy, immense sampling volume, large storage, rapid processing, and scale-up flexibility needed for diagnosis and management. Furthermore, portable immunoassay systems feature disposable capillary columns as the reaction sites and use real-time calibration for improved accuracy. It is an automated low-cost immunoassay system and designed, developed, and evaluated with several protein analytes.
Scope of Immunoassay Analyzers Market Report
The global immunoassay analyzers market research report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Immunoassay Analyzers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2021
|
|
Historic Data
|
2019–2020
|
|
Forecast Period
|
2022–2030
|
|
Segmentation
|
Application (Oncology, Cardiology, Allergy Testing, AIDS, Endocrinology, Infectious Disease Testing, Therapeutic Drug Monitoring, Autoimmune Disease, and Others), Product Type (Enzyme-Linked Immunoassay, Consumables, Accessories, Chemiluminescence Immunoassay, Immunofluorescence Analyzers, and Radioimmunoassay), and End-user (Diagnostic Laboratories, Research Institutes, Hospitals, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Immunodiagnostic Systems; Merck KGaA; Olympus Corporation; Nova Century Scientific; Inc.; Luminex Corporation; DiaSorin S.p.A.; Bio-Rad Laboratories; Inc.; Randox Laboratories Ltd.; Tecan Trading AG; Siemens; Thermo Fisher Scientific; Inc.; F. Hoffmann-La Roche Ltd.; Abbott; BD; Beckman Coulter; Inc.; Ortho Clinical Diagnostics; bioMérieux SA; Biokit S.A; The Binding Site Group Ltd.; and Quidel Corporation
|
Immunoassay Analyzers Market Segment Insights
Infectious disease testing segment to expand at a considerable CAGR
On the basis of application, the global immunoassay analyzers market is segmented into oncology, cardiology, allergy testing, aids, endocrinology, infectious disease testing, therapeutic drug monitoring, autoimmune disease, and others. The infectious disease testing segment is projected to expand at a considerable CAGR during the forecast period, due to rising infectious diseases, unhealthy sanitary habits, and cross-country migrations. The demand for diagnosis of infectious diseases is increased, as the genetic mutations in bacteria and viruses result in drug resistance.
Moreover, government initiatives and the high prevalence of infectious diseases result in the adoption of diagnostic measures. The oncology segment is anticipated to account for a major market share during the forecast period, owing to the incidence and prevalence of cancer cases taking place globally. Immunoassay analyzers are widely used for early diagnosis and monitoring of cancer. The oncology segment is expected to grow with a CAGR of over 11% during the forecast period.
Enzyme-linked immunoassay segment to hold a significant market share
Based on product type, the market is divided into enzyme-linked immunoassay, consumables, accessories, chemiluminescence immunoassay, immunofluorescence analyzers, and radioimmunoassay. The enzyme-linked immunoassay segment is expected to hold a significant share of the market in the coming years, due to its wide application in the number of diagnostic tests and high sensitivity.
Moreover, automated screening processes and the introduction of high-throughput techniques increase the demand for chemiluminescence assays. Thus, the chemiluminescence immunoassay segment is anticipated to grow at a significant growth rate.
Hospitals segment to expand at a substantial CAGR
On the basis of end-user, the global immunoassay analyzers market is segregated into diagnostic laboratories, research institutes, hospitals, and others. The hospitals segment is anticipated to expand at a substantial CAGR during the forecast period, owing to rising healthcare infrastructure and investments. The rising demand for new and improved drugs has increased the number of testing procedures.
This, in turn, increases the demand for assays, that are used to measure and monitor different types of diseases. Moreover, the research institutes segment is expected to hold a significant share of the market, due to rising demand for advanced diagnostic devices.
North America to dominate the market
In terms of regions, the global market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, owing to the high adoption rate of technologically advanced products in the region. North America dominates all other regions with a revenue share of 38.0% closely followed by Europe. Additionally, the presence of major players in the region is generating revenue for the United States.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, owing to the growing medical tourism industry in the region. Production facilities of major pharmaceutical manufacturers are moving to the Asia Pacific region, due to the advanced manufacturing infrastructure and availability of skilled labor at reasonable prices. Japan is one of the top countries for higher usage of immunoassay testing for a range of purposes and strong technological advancements. Asia Pacific region is projected to witness fast growth at a CAGR of 7% during the forecast period.
Segments
The global immunoassay analyzers market has been segmented on the basis of
Application
- Oncology
- Cardiology
- Allergy Testing
- AIDS
- Endocrinology
- Infectious Disease Testing
- Therapeutic Drug Monitoring
- Autoimmune Disease
- Others
Product Type
- Enzyme-Linked Immunoassay
- Consumables
- Accessories
- Chemiluminescence Immunoassay
- Immunofluorescence Analyzers
- Radioimmunoassay
End-user
- Diagnostic Laboratories
- Research Institutes
- Hospitals
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Immunodiagnostic Systems
- Merck KGaA
- Olympus Corporation
- Nova Century Scientific Inc.
- Luminex Corporation
- DiaSorin S.p.A.
- Bio-Rad Laboratories Inc.
- Randox Laboratories Ltd.
- Tecan Trading AG
- Siemens
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Abbott
- BD
- Beckman Coulter Inc.
- Ortho Clinical Diagnostics
- bioMérieux SA
- Biokit S.A
- The Binding Site Group Ltd.
- Quidel Corporation
Competitive Landscape
Key players competing in the global immunoassay analyzers market are Immunodiagnostic Systems; Merck KGaA; Olympus Corporation; Nova Century Scientific; Inc.; Luminex Corporation; DiaSorin S.p.A.; Bio-Rad Laboratories; Inc.; Randox Laboratories Ltd.; Tecan Trading AG; Siemens; Thermo Fisher Scientific; Inc.; F. Hoffmann-La Roche Ltd.; Abbott; BD; Beckman Coulter; Inc.; Ortho Clinical Diagnostics; bioMérieux SA; Biokit S.A; The Binding Site Group Ltd.; and Quidel Corporation.
Key players are actively engaged in R&D programs and aim at the expansion of manufacturing units to expand their consumer base and increase their product portfolio. In September 2021, Thermo Fisher Scientific, Inc. launched its fully automated analyzers.
These analyzers are named Thermo Scientific Gallery Enzyme Master and Thermo Scientific Gallery Plus Enzyme Master which are specifically designed for enzyme assay applications. In addition, In February 2021, F.Hoffman-La Roche launched the SARS-CoV-2 Rapid Antigen Test Nasal with patient self-collection.
Request For Customization
Enquiry Before Buying
Speak With Analyst
